BACK TO TOP
What is MONJUVI?
MONJUVI (tafasitamab-cxix) is a prescription medicine given in combination with lenalidomide and rituximab to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Important information I should know, including possible side effects, about MONJUVI:
MONJUVI (tafasitamab-cxix) may cause serious side effects, including infusion reactions, low blood cell counts, and infections.
The most common side effects of MONJUVI when given with lenalidomide and rituximab in people with FL include respiratory tract infections, diarrhea, rash, feeling tired or weak, muscle and bone pain, constipation, and cough.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose and not breastfeed during treatment and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.
What is MONJUVI?
MONJUVI (tafasitamab-cxix) is a prescription medicine given in combination with lenalidomide and rituximab to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at
Please see the full Prescribing Information , including Patient Information, for more information about MONJUVI.
EXPAND
What is MONJUVI?
MONJUVI (tafasitamab-cxix) is a prescription medicine given in combination with lenalidomide and rituximab to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Important information I should know, including possible side effects, about MONJUVI:
MONJUVI (tafasitamab-cxix) may cause serious side effects, including infusion reactions, low blood cell counts, and infections.
The most common side effects of MONJUVI when given with lenalidomide and rituximab in people with FL include respiratory tract infections, diarrhea, rash, feeling tired or weak, muscle and bone pain, constipation, and cough.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose and not breastfeed during treatment and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.
What is MONJUVI?
MONJUVI (tafasitamab-cxix) is a prescription medicine given in combination with lenalidomide and rituximab to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at
Please see the full Prescribing Information , including Patient Information, for more information about MONJUVI.
